4D Molecular Therapeutics(US:FDMT) GlobeNewswire News Roomยท2024-08-05 12:00Core Insights - 4D Molecular Therapeutics has strengthened its senior management team with the appointments of Dhaval Desai as Chief Development Officer, Christopher Simms as Chief Commercial Officer, and Carlos Quezada-Ruiz as SVP, Therapeutic Area Head, Ophthalmology [1][2][3] Management Appointments - Dhaval Desai will oversee late-stage product development, medical affairs, scientific communications, regulatory, and quality operations, previously serving as SVP and Chief Development Officer at Iveric Bio [1][6] - Christopher Simms will lead pre-commercial and commercial organizations starting September 25, 2024, and has extensive experience in commercial strategy and execution from his time at Iveric Bio [1][7] - Carlos Quezada-Ruiz will head the ophthalmology franchise and manage early- and late-stage clinical development, coming from Genentech where he led clinical development for VABYSMO and SUSVIMO [1][8] Strategic Focus - The company aims to transition into Phase 3 development and pre-commercialization, focusing on large market ophthalmic diseases [3][5] - The addition of experienced leaders is expected to enhance the execution of development objectives and facilitate global regulatory submissions [3][5] Ophthalmology Advisory Board - An Ophthalmology Advisory Board has been formed, chaired by Dr. Arshad Khanani, to support development strategy and registration for large market ophthalmology programs [1][4][10] - The board includes renowned retina specialists and thought leaders, providing substantial expertise in large market ophthalmology development [5][10] Product Development and Pipeline - The company is advancing six clinical-stage and one preclinical product candidate, focusing on genetic medicines for large market diseases in ophthalmology [15] - 4D-150 is highlighted as a key product with potential for sustained efficacy and reduced treatment burden for patients [4][15]